In summary, these results suggested that suppressing PI3K/AKT/mTOR pathway may be a general mechanism by which Rapamycin enhanced the anti-cancer effect of Dasatinib in NSCLC cells. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.